Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Active Biotech on private placement
Mandate

Vinge has advised Active Biotech on private placement

February 03, 2011

Active Biotech AB (publ) (NASDAQ OMX Stockholm) has carried out a private placement of new shares of SEK 375 million directed towards international institutional investors and qualified investors in Sweden.

Vinge acted for Active Biotech. Vinge’s team consisted of Erik Sjöman and Christian Lindhé.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026

Vinge advises Dunlop Aircraft Tyres in connection with its issuance of USD 93 million senior secured bonds

 Vinge has advised Dunlop, in connection with its issuance of senior secured bonds in the amount of USD 93 million, under a total framework of USD 120 million.
January 08, 2026